Welcome to our dedicated page for Bausch + Lomb news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb stock.
Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Bausch + Lomb (NYSE: BLCO) will present more than 40 scientific studies at the ARVO Annual Meeting in Denver, CO, May 3-7, 2026. Presentations cover marketed products (Xiidra, MIEBO, enVista Envy, Biotrue, INFUSE/ULTRA ONE DAY) and pipeline programs in glaucoma, AMD, neuropathic pain, and extended‑depth‑of‑focus IOLs.
Topics include clinical outcomes, contact lens care, IOL optics, dry eye treatments, antimicrobial disinfection, and preclinical/translational data for investigational candidates.
Bausch + Lomb (NYSE: BLCO) reported Q1 2026 revenue of $1.244 billion, up 9% reported and ~6% at constant currency, with GAAP net loss attributable of $71 million and adjusted EBITDA excluding acquired IPR&D of $200 million. The company raised full‑year 2026 guidance to $5.420B–$5.520B revenue and $1.010B–$1.060B adjusted EBITDA excluding acquired IPR&D.
Segment growth came from Vision Care, Surgical, and Pharmaceuticals, driven by dry eye products, premium IOLs, SiHy daily lenses and stronger MIEBO and XIIDRA sales.
Bausch + Lomb (NYSE: BLCO) published a narrative review linking certain B vitamins to lower risk and slower progression of age-related macular degeneration (AMD), synthesizing >20 human studies and ~30,000 participants. The company launched PreserVision AREDS3 with a B‑vitamin complex, available in the U.S. and rolling out to major retailers by June 2026, and is planning a long-term clinical trial to evaluate the new formulation.
Bausch + Lomb (NYSE: BLCO) released its 2025 Sustainability Impact Report and introduced The Broader Perspective framework to guide environmental, social and governance action. The report reaffirms a Net Zero by 2050 commitment and lists 2025 accomplishments in energy, waste reduction, supplier risk registration and community programs.
Bausch + Lomb (NYSE: BLCO) announced that its ONE by ONE Recycling program has collected and recycled 119,715,074 units (724,922 pounds) of used contact lenses, lens care and eye care materials in the United States as of April 16, 2026.
The program partners with TerraCycle and donates $1 per pound for qualifying 10+ pound shipments to Optometry Giving Sight.
Bausch + Lomb (NYSE:BLCO) received FDA 510(k) clearance for the Bi-Blade+ dual-port vitrectomy cutter and an Adaptive Fluidics advanced update for the Stellaris Elite system. Bi-Blade+ increases cutting speed to 25,000 cpm, raises average vitreous flow ~25%, and, with Adaptive Fluidics, showed a 62% reduction in infusion pressure and cutter vibration in bench/animal testing.
The technologies aim to improve IOP stability, efficiency and surgical control; device use is limited to Stellaris Elite systems and carries standard surgical risks.
Bausch + Lomb (NYSE: BLCO) launched the preloaded enVista Envy full range of vision intraocular lens in Europe on April 7, 2026. The diffractive premium IOL offers continuous range of vision with high dysphotopsia tolerance, ActivSync Optic energy distribution, and the new EyeGility delivery system for smooth 2 mm incision delivery.
Clinical data: 86.1% reported little to no dysphotopsia; Canadian study showed 95.4% little to no difficulty with near vision and 93% satisfaction.
Bausch + Lomb (NYSE: BLCO) will present 45 scientific presentations and posters at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., April 10–13, 2026. Topics span IOLs, MIGS, dry eye therapies, osmolarity testing, excimer laser trabeculostomy and real-world outcomes.
Events include company-hosted sessions April 9–11 and multiple paper and poster presentations reporting clinical evaluations, real-world evidence and device performance across the company’s portfolio.
Bausch + Lomb (NYSE: BLCO) will release its first-quarter 2026 financial results on Wednesday, April 29, 2026, and will host a conference call and live webcast at 8 a.m. ET.
All presentation materials will be posted on the company's Investor Relations website prior to the call. Replay access will be available through May 13, 2026, with passcode 53393.
Bausch + Lomb (NYSE:BLCO) announced positive 24-month pivotal U.S. trial results for the implant-free ELIOS System for open-angle glaucoma. Key outcomes: 76% of patients achieved ≥20% unmedicated IOP reduction, mean unmedicated DIOP fell by 7.4 mmHg, and 82% were medication-free at 23 months.
The ELIOS procedure reported no intraoperative complications and a postoperative adverse event rate similar to cataract surgery. ELIOS is CE marked in Europe but has not been reviewed by the FDA in the U.S.